Le Lézard
Classified in: Health, Science and technology
Subject: PER

Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer


AMSTERDAM, Dec. 5, 2023 /PRNewswire/ -- Kling Bio ("Kling" or "the Company"), a biotech company developing antibody-based drugs against targets identified from its immortalized B-cell platform, is pleased to announce the appointment of Dr Stefano Gullà as Chief Scientific Officer.

Dr Gullà is a seasoned industry veteran with over 15 years of experience in biotherapeutics discovery and development. Prior to joining Kling, Dr Gullà held senior positions at Pfizer, Agenus, Flagship, and RVAC where he led the discovery and development of its first-in-class therapeutics with applications in immuno-oncology and autoimmunity.

Commenting on the appointment, Michael Koslowski, Chief Executive Officer of Kling Bio, said: "Kling will benefit immensely from Stefano's proven leadership skills and in-depth scientific knowledge. I am confident Stefano will help guide and execute our vision for Kling during this pivotal phase of Company growth, as we accelerate to become a world-leading drug discovery and development company."

Stefano Gullà, new Chief Scientific Officer of Kling Bio, commented: "Kling's technology is a powerful discovery engine that enables simultaneous and unbiased identification of new targets and therapeutic antibodies. I am excited about the potential to scale this clinically proven platform, focusing on cancer and emerging infectious diseases, and look forward to working with Kling's exceptionally talented leadership team to continue building value for patients by advancing life changing medicines into the clinic." 

In addition to his successful track record of biotherapeutics discovery and development, Stefano brings exceptional entrepreneurial experience to Kling. In 2016, Stefano founded Abcuro, a biotech company focused on developing novel therapeutics for cancer and autoimmune diseases, where he held the positions of CEO and CSO. He led Abcuro from inception into the clinic and raised over $60 million in venture funding. Stefano is passionate about bringing innovative therapies to patients. He obtained a Bachelor of Science in Biochemistry and Doctor of Philosophy (Ph.D.) degrees from Northeastern University, before completing a postdoctoral training at the Massachusetts Institute of Technology (MIT).

About Kling Bio

Kling Biotherapeutics is a clinical-stage, privately held biotech company focused on discovery and development of antibody based therapeutics. The company is headquartered in Amsterdam, Netherlands with a fully owned IP portfolio that covers platform technologies Kling-Select and Kling-Evolve for the simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells.

Kling-Select relies on a fully-owned and clinically-validated B cell immortalization technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses. This technology has successfully identified novel neutralising antibodies for various infectious diseases such as RSV (nirsevimab/Beyfortus), Covid, and Influenza. More recently, Kling-Select has been applied to peripheral and tumor-infiltrating B cells derived from cancer patients and produced a portfolio of novel and selective target-antibody pairs. The unbiased nature of this discovery platform allows identification of novel targets and unique epitopes inaccessible to traditional target discovery approaches.

Kling-Evolve enables the ex vivo affinity maturation of B cell clones against targets of interest. This powerful technology can be used for the rapid evolution of neutralizing antibodies against emerging viral variants or for affinity and selectivity improvement of oncology assets.

Kling Biotherapeutics is progressing a unique pipeline of oncology programs with KBA1412, a first-in-class CD9 antibody, being tested in a Phase 1 clinical trial.


These press releases may also interest you

at 03:59
Medivir AB , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Life Science Day in Gothenburg on March 6, 2024. CEO Jens Lindberg...

at 03:36
The European Society of Gynecological Oncology (ESGO) 2024 Conference has recently made selected abstracts available online. The abstract (abstract # 251) that details results from the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and...

at 03:30
Samyang Group announced that KCI (CEO Jinyong Lee), a subsidiary specializing in cosmetics and personal care materials, won 'Platinum Medal', the highest grade, in the 2024 Sustainability Rating from 'EcoVadis', a global ESG rating agency....

at 03:00
Insightec, a pioneer and global leader in focused ultrasound, is pleased to announce that its transcranial MR-guided focused ultrasound (MRgFUS) has been granted NUB status 1 for the treatment of essential tremor (ET) in Germany. This significant...

at 02:44
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its enterprise imaging solution to yet another healthcare provider in the US Midwest. The healthcare provider will utilize the radiology module to unify the...

at 02:05
The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in two types of cancer. One MAA is for the...



News published on and distributed by: